Antonella Chadha Santuccione, MD, Co-founder and CEO of the Women’s Brain Project and Chief Medical Officer at Altoida Inc., comments on the development of a digital cognitive assessment with augmented reality and machine learning, for use in Alzheimer’s disease clinical trials and beyond. Altoida have developed a digital biomarker platform able to evaluate cognitive and functional impairment in neurological disease. The 10-minute test can be carried out on a portable, smart device, measuring cognitive and motoric functions via multimodal digital biomarkers. Motoric and augmented reality tasks are designed to reflect activities of daily living and can detect numerous subtle features, such as micro-movements, reaction times, micro-errors, and navigation trajectories that are used to train predictive algorithms. The platform can be used as a readout system in clinical trials and, in the future, may be a valuable tool for early diagnosis and sensitive monitoring of disease progression in clinical practice. This interview took place at the AD/PD™ 2023 congress in Gothenburg, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
